In this paper we review some of the preclinical findings which have led us to believe that immunotherapy with interleukin 2 (IL2)/lymphokine activated killer (LAK) cells may be a feasible approach in the management of acute myeloid leukemia. The main clinical and biological results so far obtained with IL2 treatment, and the currently ongoing protocols and strategies are discussed.

Interleukin 2 (IL2) in the management of acute myeloid leukemia: clinical and biological findings / Foa, Roberto; Meloni, Giovanna; Guarini, Anna; Vignetti, Marco; D., Marchis; S., Tosti; A., Gilio Tos; F., Vischia; Mandelli, Franco; F., Gavosto. - In: LEUKEMIA. - ISSN 0887-6924. - STAMPA. - 6(1992), pp. 115S-116S. ((Intervento presentato al convegno 15TH SYMP OF THE INTERNATIONAL ASSOC FOR COMPARATIVE RESEARCH ON LEUKEMIA AND RELATED DISEASES tenutosi a PADUA, ITALY nel OCT 06-11, 1991.

Interleukin 2 (IL2) in the management of acute myeloid leukemia: clinical and biological findings

FOA, Roberto;MELONI, Giovanna;GUARINI, Anna;VIGNETTI, Marco;MANDELLI, Franco;
1992

Abstract

In this paper we review some of the preclinical findings which have led us to believe that immunotherapy with interleukin 2 (IL2)/lymphokine activated killer (LAK) cells may be a feasible approach in the management of acute myeloid leukemia. The main clinical and biological results so far obtained with IL2 treatment, and the currently ongoing protocols and strategies are discussed.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/501652
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 4
social impact